Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine TumorsJonathan Strosberg, Eric P. Krenning, Thomas M. O’Dorisio et al.|New England Journal of Medicine|2017Cited by 3.2k
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 TrialJonathan Strosberg, Edward M. Wolin, Beth Chasen et al.|Journal of Clinical Oncology|2018Cited by 388
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer PatientsKimberly R. Kalli, Keith L. Knutson, Matthew S. Block et al.|Clinical Cancer Research|2018Cited by 97
Clonal Hematopoiesis in Patients With Neuroendocrine Tumor Treated With Lutetium-177 and the Risk of Thrombocytopenia: A Prospective StudyYael Kusne, Mohamad Bassam Sonbol, Terra L. Lasho et al.|JCO Precision Oncology|2024Cited by 5
Abstract 5928: Prevalence of clonal hematopoiesis in neuroendocrine tumor patients prior to lutetium 177 dotatate therapy (Lu177): A prospective trial of 36 patientsYael Kusne, Mohamad Bassam Sonbol, Terra Lasho et al.|Cancer Research|2023Cited by 0